Medpace Holdings is a holding company. Through its subsidiaries, Co. is a global provider of clinical research-based drug and medical device development services. Co. provides a suite of services supporting the entire clinical development process from Phase I to Phase IV across a range of therapeutic areas. Co.'s clinical development services include medical department, clinical trial management, data-driven feasibility, study start-up, patient recruitment and retention, clinical monitoring, risk-based monitoring, regulatory affairs, medical writing, biometrics and data sciences, pharmacovigilance, main laboratory, central laboratory, bioanalytical laboratory, clinics and quality assurance. The MEDP average annual return since 2016 is shown above.
The Average Annual Return on the MEDP average annual return since 2016 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether MEDP average annual return since 2016 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MEDP average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|